Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canagliflozin vs Nicotinamide Riboside: Nicotinamide Riboside has the stronger overall evidence (5.5 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Nicotinamide Riboside wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
2 of 2 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Canagliflozin and Nicotinamide Riboside have evidence — compare verdict strength side-by-side.
Off-label use mirrors diabetes dosing (e.g. 100–300 mg once daily before the first meal) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (canagliflozin)
300–500 mg daily
Morning with breakfast, Split dosing (morning and midday) for doses above 500 mg
Nicotinamide Riboside Chloride capsules or powder
Unknown in humans
Months to years
Weeks to months
Throughout use
1–2 weeks
4–8 weeks
8–16 weeks
4–8 weeks
Canagliflozin extends life span in genetically heterogeneous male but not female mice.
JCI insight (2020) · Animal
NIA Interventions Testing Program: canagliflozin extended lifespan in male mice
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial (empagliflozin, same class)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
The New England journal of medicine (2021) · Rct
EMPEROR-Preserved randomized trial (empagliflozin)
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
Journal of cachexia, sarcopenia and muscle (2025) · Meta analysis
Systematic review and meta-analysis of RCTs evaluating NMN and NR effects on skeletal muscle mass and function
NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
Ageing research reviews (2026) · Systematic review
PRISMA-guided systematic review of both preclinical and clinical NAD+ supplementation literature
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.
Experimental gerontology (2020) · Systematic review
Systematic review of 147 articles (113 preclinical, 34 clinical) on NAD+ precursor therapy
Based on 8-week RCT showing dose-dependent increases of 22%, 51%, and 142% at 100, 300, and 1000mg respectively. Individual response varies significantly (30% show variable response). NR-SAFE trial confirmed safety up to 2000mg.
AI-estimated from published studies. Interpret as directional guidance.
Nicotinamide Riboside has a higher evidence score (5.5/10 vs 4.5/10) and wins in 3 of 3 categories.
For support heart health, Canagliflozin has a higher relevance score (70 vs 62).
No known interactions between Canagliflozin and Nicotinamide Riboside have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.